Dermatology: Practical and Conceptual


Observation  |  Dermatol Pract Concept 2015;5(1):11 59

DERMATOLOGY PRACTICAL & CONCEPTUAL
www.derm101.com

Case presentations
Case 1
A 61-year-old man presented with multiple small, reddish, 

eroded papules located on his chest (Figure 1A). Histo-

Dermoscopic clues to diagnose 
acantholytic dyskeratosis

Francesca Specchio1, Giuseppe Argenziano2, Danica Tiodorovic-Zivkovic3, Elvira Moscarella2, 
Aimilios Lallas2, Iris Zalaudek4, Caterina Longo2

1 Department of Dermatology, University of Rome, Tor Vergata, Italy

2 Dermatology and Skin Cancer Unit, Arcispedale S. Maria Nuova, IRCCS, Reggio Emilia, Italy

3 Clinic of Dermatovenerology, Clinical Center of Nis, Medical Faculty, University of Nis, Serbia

4 Department of Dermatology, Medical Universiy of Graz, Graz, Austria

Key words: acantholytic dyskeratosis, dermoscopy

Citation: Specchio F, Argenziano G, Tiodorovic-Zivkovic D, Moscarella E, Lallas A, Zalaudek I, Longo C. Dermoscopic clues to diagnose 
acantholytic dyskeratosis. Dermatol Pract Concept 2015;5(1):11. doi: 10.5826/dpc.05011

Received: September 8, 2014; Accepted: October 16, 2014; Published: January 30, 2015

Copyright: ©2015 Specchio et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: None.

Competing interests: The authors have no conflicts of interest to disclose.

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data. Drs. 
Specchio and Longo wrote the manuscript. All authors revised it critically for important intellectual content. All authors gave the final 
approval of this version to be published.

Corresponding author: Caterina Longo, MD, PhD, Dermatology and Skin Cancer Unit, Arcispedale Santa Maria Nuova-IRCCS, Viale 
Risorgimento, 80, 42100 Reggio Emilia, Italy. Tel. 390522295612; Fax. 390594224271. Email: longo.caterina@gmail.com

Figure 1. (A) Clinical examination of case 1 showed multiple confluent erythematous papules in a patient with Grover’s disease. (B) Clini-

cally, multiple reddish papules were observed on the chest of a patient with stage IV melanoma treated with vemurafenib. (Copyright: ©2015 

Specchio et al.)

pathologic examination revealed the typical findings of 

Grover’s disease.

Case 2
A 47-year-old woman was treated with vemurafenib for stage 

mailto:longo.caterina@gmail.com


60 Observation  |  Dermatol Pract Concept 2015;5(1):11

benign and malignant lesions, such as cutaneous squamous-

cell carcinoma, verrucal keratosis, plantar hyperkeratosis, 

hair follicle changes, panniculitis, and photosensitivity [2], 

along with widespread eruptions with histologic features of 

acantholytic dyskeratosis [3]. Acantholytic dyskeratoma has 

been previously reported in association with other chemo-

therapeutics, including the epidermal growth factor receptor 

inhibitor cetuximab; however, the pathogenesis of acantho-

lytic dyskeratosis is still unclear. Two hypotheses have been 

postulated. One theory is that the accumulation in the skin 

of chemotherapy metabolites by sweating may be related to 

the development of dyskeratosis and acantholysis; another 

theory supposes that acantholytic dyskeratosis may represent 

an off-target effect of small-molecule kinase inhibitors [1].

Recognition of cutaneous side effects occurring during 

BRAF-inhibitor therapy is essential for patient management. 

Acantholytic dyskeratomas can be easily diagnosed by using 

dermoscopy. In fact, in acantholytic lesions, dermoscopy 

allows the visualization of a stereotypical pattern [4], which 

also assists in the differentiation of these benign lesions from 

malignancy, such as keratoacanthoma or invasive squamous 

cell carcinoma that may also occur as a complication of 

BRAF inhibitor therapy. Typically, these papules display a 

central star-like pattern of brown scales that are otherwise 

not detectable at clinical examination. This dermoscopic 

pattern has been described to be peculiar for Grover’s disease 

and solitary acantholytic dyskeratoma [4]. Interestingly, our 

study shows the characteristic dermoscopic star-like pattern 

can be observed in acantholytic dyskeratotic lesions occur-

ring during treatment with BRAF-inhibitors, as previously 

reported [3].

In conclusion, our case underlines the importance of der-

moscopy to improve the recognition of acantholytic dyskera-

tomas (in Grover’s disease and in patients under vemurafenib 

therapy), a skin eruption that is usually difficult to diagnose 

by naked eye.

References

1.  Gupta M, Huang V, Linette G, Cornelius L. Unusual complication 

of vemurafenib treatment of metastatic melanoma: exacerbation 

of acantholytic dyskeratosis complicated by Kaposi varicelliform 

eruption. Arch Dermatol 2012;148(8):966-68.

2.  Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of 

RAF inhibitors. Lancet Oncol 2013;14(1):e11-8.

3.  Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects 

associated with BRAF inhibitor therapy: A clinicopathologic study. 

J Am Acad Dermatol 2012;67(6):1265-72.

4.  Giacomel J, Zalaudek I, Argenziano G. Dermatoscopy of Grover’s 

disease and solitary acantholytic dyskeratoma shows a brown, 

star-like pattern. Australas J Dermatol 2012;53(4): 315-16.

IV melanoma, having been referred because of the recent 

onset of multiple asymptomatic reddish papules located on 

her chest (Figure 1B). These lesions represented a skin rash 

of acantholytic dyskeratoma occurring while under vemu-

rafenib treatment that spontaneously disappeared over the 

next few weeks.

The dermoscopic evaluation of the lesions in both cases 

showed a central yellowish to brown star-like pattern over-

lying a pinkish homogeneous structureless area (Figure 2A 

and B).

Conclusions

Treatment with vemurafenib, a small-molecule BRAF inhib-

itor, has led to significant improvement of prognosis in 

patients with advanced melanoma. Similar to other kinase 

inhibitors, the use of vemurafenib has been accompanied by 

several dermatologic adverse events [1]. These include both 

Figure 2. (A) Dermoscopic evaluation of case 1 displayed a central 

yellowish to brown star-like pattern overlying a pinkish homoge-

neous structureless area similarly to the ones observed in case 2 (B). 

(Copyright: ©2015 Specchio et al.)